No Data
Express News | NewAmsterdam Pharma Company NV - to Report Phase 3 Brooklyn Trial Data on July 29
Express News | NewAmsterdam Pharma to Announce Topline Data From Pivotal Phase 3 Brooklyn Clinical Trial Evaluating Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
Piper Sandler Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $37
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and NewAmsterdam Pharma Company (NAMS)
Piper Sandler Sticks to Its Buy Rating for NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Board Reshuffles, Welcomes Industry Experts